Developer docs
API playgroundTry for free, no card

Search company profiles

Invivoscribe, Inc.

Full company profile

uuid0007ard

Namestring
Invivoscribe, Inc.
Legal namestring
Invivoscribe, Inc.
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Invivoscribe is a privately held, San Diego-based precision diagnostics company founded in 1995, focused on hematology-oncology. The company develops and commercializes next-generation sequencing (NGS) assays, companion diagnostics (CDx), measurable residual disease (MRD) testing kits, and proprietary bioinformatics software used by pharmaceutical developers and clinical laboratories worldwide. Its product portfolio spans gene-rearrangement assays (IdentiClone), FLT3 mutation testing (LeukoStrat CDx), KMT2A-rearrangement assays, and the recently launched PrepQuant sample-preparation system, supported by an automated analysis pipeline built around its LymphoTrack bioinformatics platform.

The company operates through three integrated business lines: (1) pharma-sponsored companion-diagnostic development and clinical-trial services anchored by named partners including Astellas, Daiichi Sankyo, Novartis, and Kronos Bio; (2) IVDR- and FDA-cleared assay and software kits sold to research and clinical laboratories across 160+ countries; and (3) clinical testing services delivered through its LabPMM laboratory network in the United States, Germany, and Japan on a fee-for-service basis. Regionally, the company is structured around wholly owned subsidiaries in France and China, with an active footprint in Shanghai and an expanding Japan operation under recently appointed general-management leadership.

Recent regulatory and product milestones include IVDR Class C certification for the IdentiClone Dx IGH Assay (March 2026), launch of the LeukoStrat KMT2A + MRD Assay (February 2026), launch of the PrepQuant System (April 2026), and ongoing registration submissions in the United Kingdom, Switzerland, and China. Strategic partnerships with Hitachi High-Tech (automation, 2022) and Complete Genomics (sequencing platform, 2023) extend the company's reach into sample-prep automation and into lower-cost sequencing for the China market.

Short descriptiontext

Invivoscribe is a privately held precision diagnostics company founded in 1995 that develops NGS assays, companion diagnostics, and bioinformatics software for hematologic malignancies. It serves pharmaceutical partners and clinical laboratories across 160+ countries via its LabPMM clinical lab network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, companion diagnostics, minimal residual disease, hematologic malignancy testing, clinical laboratory services
Industry4 codes
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics for Hematologic Malignancies
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Assay Kits and Reagents Sales
TypeOne Time License
Description

Sale of standardized cGMP manufactured diagnostic assay kits (RUO, CE-IVDR, IVD), analyte specific reagents (ASRs), and DNA/RNA controls to clinical laboratories and research institutions worldwide.

invivoscribe.com
2Clinical Laboratory Testing Services (LabPMM)
TypeProfessional Services
Description

Fee-for-service clinical lab testing through the LabPMM network providing internationally standardized testing of biomarkers for hematologic malignancies including flow cytometry, NGS panels, MRD testing, and clonality testing.

invivoscribe.com
3Companion Diagnostic Development Partnerships
TypeLicensing Royalties
Description

Co-development and regulatory partnership revenue from pharmaceutical companies for CDx development, validation, and approval for targeted therapies. Includes CDx testing services supporting clinical trials.

invivoscribe.com
4Bioinformatics Software Licensing
TypeSubscription Recurring
Description

Licensing of LymphoTrack software (desktop, enterprise, MRD variants) and LeukoStrat software for NGS data analysis and MRD tracking.

invivoscribe.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Assay kits and reagents (RUO, IVD, CE-IVDR)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Unit-based pricing for assay kits, controls, and reagents; pricing varies by product type and regulatory classification. Contact sales for quote.

invivoscribe.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1LymphoTrack
Description

NGS-based clonality and MRD testing assays and software for B- and T-cell receptor gene rearrangement analysis

invivoscribe.com
+7 more records
Core offering1 text field

Invivoscribe develops, manufactures, and commercializes cGMP precision diagnostic assay kits, bioinformatics software, and clinical laboratory services for hematologic malignancies, with a focus on companion diagnostics (CDx), clonality testing, and minimal residual disease (MRD) monitoring. Its flagship LeukoStrat CDx FLT3 Mutation Assay was the world's first FDA-approved companion diagnostic for AML and is approved for multiple targeted therapies across the USA, EU, Japan, and the UK. The company also operates the LabPMM global clinical laboratory network providing internationally standardized biomarker testing for patient care and pharmaceutical clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • MRD detection sensitivity down to 0.005% (5×10⁻⁵) with digital PCR-based LeukoStrat KMT2A + MRD Assay, surpassing traditional cytogenetics and FISH methods
+2 more records
Product overview1 text field

Invivoscribe is a global biotechnology company specializing in precision diagnostics for hematology-oncology with over 30 years of experience. The company offers a comprehensive portfolio of products organized around several core platforms: (1) LymphoTrack Solutions - a suite of NGS assays and bioinformatics software for clonality, somatic hypermutation, and MRD testing; (2) LeukoStrat CDx FLT3 Mutation Assay - a globally standardized companion diagnostic approved for three drugs across US, EU, and Japan markets; (3) PrepQuant System - an automated sample preparation platform developed with Hitachi High-Tech Corporation for nucleic acid extraction and quantification; and (4) LabPMM clinical laboratory services - an internationally standardized testing network with labs in USA, Germany, and Japan. The product portfolio also includes digital PCR-based assays (LeukoStrat KMT2A + MRD Assay), PCR-based IVD assays (IdentiClone Dx IGH Assay), and targeted gene panels (MyAML, MyMRD). The company provides CE-marked IVDs, RUO assays, ASRs, and controls/reagents for the hematology-oncology diagnostics market.

Product and service1 record
1LymphoTrack Solutions
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-02
Description

Partnership to develop and commercialize biomarker tests for oncology and cancer research. Enables Invivoscribe's LymphoTrack assays and LeukoStrat MRD assays to run on Complete Genomics' DNBSEQ-G99 sequencing platform, expanding platform compatibility for customers. Jointly published performance comparison white papers demonstrating assay equivalency between DNBSEQ-G99 and Illumina MiSeq platforms.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-08-16
Description

Companion diagnostic development partnership for use with entospletinib, Kronos Bio's investigational compound being developed for patients with AML. Invivoscribe developing CDx to identify appropriate patient populations for the therapeutic candidate.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-05-09
Description

Strategic collaboration to develop and commercialize molecular diagnostic products. Jointly developed the PrepQuant System, an automated sample preparation platform integrating nucleic acid extraction, concentration, and quantification. First commercial shipments targeted for August 2026 in North America and January 2027 in Europe. The partnership combines Hitachi High-Tech's automation expertise with Invivoscribe's molecular diagnostics capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-27
Description

CDx partnership for XOSPATA (gilteritinib fumarate) for FLT3-mutated AML. LeukoStrat CDx FLT3 Mutation Assay received FDA approval as companion diagnostic and national reimbursement in Japan. European Commission approved the therapy with validated tests including Invivoscribe's assay.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-19
Description

CDx partnership for VANFLYTA (quizartinib) for FLT3-ITD AML. LeukoStrat CDx FLT3 Mutation Assay received MHLW approval in Japan and EMA/EU approval for VANFLYTA therapy. Assay expanded to include specimens collected in EDTA. Submission to NMPA in China for regulatory approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-04-28
Description

CDx partnership for Rydapt (midostaurin) for newly diagnosed FLT3-mutated AML. The LeukoStrat CDx FLT3 Mutation Assay was the world's first FDA-approved companion diagnostic for AML, enabling patient selection for Novartis therapy. Invivoscribe received national reimbursement for the CDx assay in Japan.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-02-14
Description

Long-term collaboration agreement for development and release of NGS-based IVD assay kits. Invivoscribe develops LymphoTrack assays compatible with Illumina sequencing platforms (MiSeq, MiSeq i100, NextSeq 1000/2000) using proprietary adapters and tracking tags. Includes co-marketing and co-development of NGS-based diagnostic solutions.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-02-09
Description

Long-term collaboration to develop and commercialize immuno-oncology tests. LymphoTrack assays validated on Thermo Fisher Ion S5 and Ion PGM NGS platforms, expanding customer access to Invivoscribe's molecular diagnostics portfolio through Thermo Fisher's installed base.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialized oncology reference lab offering hematologic malignancy testing, MRD assays, and CDx services in the US and internationally. Direct competitor to Invivoscribe's LabPMM clinical lab and CDx franchise with significant overlap in lymphoma/leukemia molecular diagnostics.

TypeDirect peer
Description

ClonoSEQ MRD assay and immunoSEQ clonality platform overlap directly with Invivoscribe's LymphoTrack and LeukoStrat MRD products for blood cancer MRD monitoring. Both companies use NGS-based receptor gene sequencing for clonal tracking.

TypeBroad incumbent
Description

Broad oncology NGS profiling and CDx developer owned by Roche; competes with Invivoscribe for biopharma CDx partnerships and hematologic panel testing, especially with its heme panel and global pharma services reach.

TypeDirect peer
Description

Cancer genomics company offering tumor profiling and MRD solutions (NeXT Personal) for biopharma and clinical use; competes with Invivoscribe's NGS panel/CDx/molecular diagnostic offering in oncology biomarker work.

TypeBroad incumbent
Description

Major molecular diagnostics and sample technologies company with companion diagnostic, IVD assay, and bioinformatics offerings; broad incumbent competing with Invivoscribe's assay kits, CDx, and bioinformatics software businesses.

TypeBroad incumbent
Description

Labcorp acquired sequencing-based diagnostics and CDx assets including ArcherDX for hematologic fusion/mutation detection and inherited cancer testing; competes broadly with Invivoscribe's oncology NGS and CDx services through its central lab network.

TypeDirect peer
Description

Molecular diagnostics business of Bio-Techne that develops quantitative PCR kits (e.g., BCR-ABL, JAK2) for blood cancer monitoring with pharma CDx experience; competes with Invivoscribe's PCR-based IdentiClone, LeukoStrat, and quantitative oncology kits.

TypeBroad incumbent
Description

Global hematology diagnostics leader with cell analyzers, flow cytometry, and growing molecular hemato-oncology franchise; broad incumbent in hematologic malignancy diagnostics overlapping Invivoscribe's LabPMM flow and NGS services.

TypeEmerging player
Description

Liquid biopsy oncology testing and CDx company; while initially focused on solid tumors, expansion into blood-based cancer monitoring overlaps with Invivoscribe's hematologic MRD ambitions and CDx/biopharma partnership model.

TypeEmerging player
Description

Molecular profiling company developing tissue and blood-based oncology biomarker assays and CDx partnerships for hematologic and solid tumor indications; an emerging peer in biomarker-driven CDx development similar to Invivoscribe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invivoscribe, Inc.

Molecular Diagnostics for Hematologic Malignanciesinvivoscribe.com

Invivoscribe is a privately held precision diagnostics company founded in 1995 that develops NGS assays, companion diagnostics, and bioinformatics software for hematologic malignancies. It serves pharmaceutical partners and clinical laboratories across 160+ countries via its LabPMM clinical lab network.

What Invivoscribe, Inc. does

Invivoscribe is a privately held, San Diego-based precision diagnostics company founded in 1995, focused on hematology-oncology. The company develops and commercializes next-generation sequencing (NGS) assays, companion diagnostics (CDx), measurable residual disease (MRD) testing kits, and proprietary bioinformatics software used by pharmaceutical developers and clinical laboratories worldwide. Its product portfolio spans gene-rearrangement assays (IdentiClone), FLT3 mutation testing (LeukoStrat CDx), KMT2A-rearrangement assays, and the recently launched PrepQuant sample-preparation system, supported by an automated analysis pipeline built around its LymphoTrack bioinformatics platform.

The company operates through three integrated business lines: (1) pharma-sponsored companion-diagnostic development and clinical-trial services anchored by named partners including Astellas, Daiichi Sankyo, Novartis, and Kronos Bio; (2) IVDR- and FDA-cleared assay and software kits sold to research and clinical laboratories across 160+ countries; and (3) clinical testing services delivered through its LabPMM laboratory network in the United States, Germany, and Japan on a fee-for-service basis. Regionally, the company is structured around wholly owned subsidiaries in France and China, with an active footprint in Shanghai and an expanding Japan operation under recently appointed general-management leadership.

Recent regulatory and product milestones include IVDR Class C certification for the IdentiClone Dx IGH Assay (March 2026), launch of the LeukoStrat KMT2A + MRD Assay (February 2026), launch of the PrepQuant System (April 2026), and ongoing registration submissions in the United Kingdom, Switzerland, and China. Strategic partnerships with Hitachi High-Tech (automation, 2022) and Complete Genomics (sequencing platform, 2023) extend the company's reach into sample-prep automation and into lower-cost sequencing for the China market.

Invivoscribe, Inc. firmographics

Firmographics
Name
Invivoscribe, Inc.
Legal name
Invivoscribe, Inc.
Website
https://invivoscribe.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
101–250 employees
Short description
Invivoscribe is a privately held precision diagnostics company founded in 1995 that develops NGS assays, companion diagnostics, and bioinformatics software for hematologic malignancies. It serves pharmaceutical partners and clinical laboratories across 160+ countries via its LabPMM clinical lab network.
Ownership category
akta.pro rank

Invivoscribe, Inc. industry classification

Industry
Product category
Molecular Diagnostics for Hematologic Malignancies
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAJ
Companion Diagnostics (CDx) Development & Trial Testing Support
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular diagnostics
  • Companion diagnostics
  • Minimal residual disease
  • Hematologic malignancy testing
  • Clinical laboratory services

Where Invivoscribe, Inc. is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Invivoscribe, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Assay Kits and Reagents Sales: Sale of standardized cGMP manufactured diagnostic assay kits (RUO, CE-IVDR, IVD), analyte specific reagents (ASRs), and DNA/RNA controls to clinical laboratories and research institutions worldwide.
  2. Clinical Laboratory Testing Services (LabPMM): Fee-for-service clinical lab testing through the LabPMM network providing internationally standardized testing of biomarkers for hematologic malignancies including flow cytometry, NGS panels, MRD testing, and clonality testing.
  3. Companion Diagnostic Development Partnerships: Co-development and regulatory partnership revenue from pharmaceutical companies for CDx development, validation, and approval for targeted therapies. Includes CDx testing services supporting clinical trials.
  4. Bioinformatics Software Licensing: Licensing of LymphoTrack software (desktop, enterprise, MRD variants) and LeukoStrat software for NGS data analysis and MRD tracking.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAssay kits and reagents (RUO, IVD, CE-IVDR)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Invivoscribe, Inc. product offering

Product offering

Core offering

Invivoscribe develops, manufactures, and commercializes cGMP precision diagnostic assay kits, bioinformatics software, and clinical laboratory services for hematologic malignancies, with a focus on companion diagnostics (CDx), clonality testing, and minimal residual disease (MRD) monitoring. Its flagship LeukoStrat CDx FLT3 Mutation Assay was the world's first FDA-approved companion diagnostic for AML and is approved for multiple targeted therapies across the USA, EU, Japan, and the UK. The company also operates the LabPMM global clinical laboratory network providing internationally standardized biomarker testing for patient care and pharmaceutical clinical trials.

Product overview

Invivoscribe is a global biotechnology company specializing in precision diagnostics for hematology-oncology with over 30 years of experience. The company offers a comprehensive portfolio of products organized around several core platforms: (1) LymphoTrack Solutions - a suite of NGS assays and bioinformatics software for clonality, somatic hypermutation, and MRD testing; (2) LeukoStrat CDx FLT3 Mutation Assay - a globally standardized companion diagnostic approved for three drugs across US, EU, and Japan markets; (3) PrepQuant System - an automated sample preparation platform developed with Hitachi High-Tech Corporation for nucleic acid extraction and quantification; and (4) LabPMM clinical laboratory services - an internationally standardized testing network with labs in USA, Germany, and Japan. The product portfolio also includes digital PCR-based assays (LeukoStrat KMT2A + MRD Assay), PCR-based IVD assays (IdentiClone Dx IGH Assay), and targeted gene panels (MyAML, MyMRD). The company provides CE-marked IVDs, RUO assays, ASRs, and controls/reagents for the hematology-oncology diagnostics market.

Differentiator

Problem solved

Functional benefit

Brands

  • LymphoTrack: NGS-based clonality and MRD testing assays and software for B- and T-cell receptor gene rearrangement analysis
  • LeukoStrat
  • IdentiClone
  • PrepQuant
  • MyAML
  • MyMRD
  • LymphoQuant
  • LymphoTrack Dx

Products and services

  • LymphoTrack Solutions

Quantifiable outcome

  • MRD detection sensitivity down to 0.005% (5×10⁻⁵) with digital PCR-based LeukoStrat KMT2A + MRD Assay, surpassing traditional cytogenetics and FISH methods
  • +2 more outcomes

Companies that use Invivoscribe, Inc.

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Invivoscribe, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature6 records

Invivoscribe, Inc. partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • Complete Genomics (BGI)coreTechnology or Integration · 2 June 2023Partnership to develop and commercialize biomarker tests for oncology and cancer research. Enables Invivoscribe's LymphoTrack assays and LeukoStrat MRD assays to run on Complete Genomics' DNBSEQ-G99 sequencing platform, expanding platform compatibility for customers. Jointly published performance comparison white papers demonstrating assay equivalency between DNBSEQ-G99 and Illumina MiSeq platforms.
  • Kronos BiomajorStrategic or Co-development Partner · 16 August 2022Companion diagnostic development partnership for use with entospletinib, Kronos Bio's investigational compound being developed for patients with AML. Invivoscribe developing CDx to identify appropriate patient populations for the therapeutic candidate.
  • Hitachi High-Tech CorporationcoreTechnology or Integration · 9 May 2022Strategic collaboration to develop and commercialize molecular diagnostic products. Jointly developed the PrepQuant System, an automated sample preparation platform integrating nucleic acid extraction, concentration, and quantification. First commercial shipments targeted for August 2026 in North America and January 2027 in Europe. The partnership combines Hitachi High-Tech's automation expertise with Invivoscribe's molecular diagnostics capabilities.
  • Astellas PharmacoreStrategic or Co-development Partner · 27 September 2019CDx partnership for XOSPATA (gilteritinib fumarate) for FLT3-mutated AML. LeukoStrat CDx FLT3 Mutation Assay received FDA approval as companion diagnostic and national reimbursement in Japan. European Commission approved the therapy with validated tests including Invivoscribe's assay.
  • Daiichi SankyocoreStrategic or Co-development Partner · 19 June 2019CDx partnership for VANFLYTA (quizartinib) for FLT3-ITD AML. LeukoStrat CDx FLT3 Mutation Assay received MHLW approval in Japan and EMA/EU approval for VANFLYTA therapy. Assay expanded to include specimens collected in EDTA. Submission to NMPA in China for regulatory approval.
  • NovartiscoreStrategic or Co-development Partner · 28 April 2017CDx partnership for Rydapt (midostaurin) for newly diagnosed FLT3-mutated AML. The LeukoStrat CDx FLT3 Mutation Assay was the world's first FDA-approved companion diagnostic for AML, enabling patient selection for Novartis therapy. Invivoscribe received national reimbursement for the CDx assay in Japan.
  • IlluminacoreStrategic or Co-development Partner · 14 February 2017Long-term collaboration agreement for development and release of NGS-based IVD assay kits. Invivoscribe develops LymphoTrack assays compatible with Illumina sequencing platforms (MiSeq, MiSeq i100, NextSeq 1000/2000) using proprietary adapters and tracking tags. Includes co-marketing and co-development of NGS-based diagnostic solutions.
  • Thermo Fisher ScientificmajorStrategic or Co-development Partner · 9 February 2016Long-term collaboration to develop and commercialize immuno-oncology tests. LymphoTrack assays validated on Thermo Fisher Ion S5 and Ion PGM NGS platforms, expanding customer access to Invivoscribe's molecular diagnostics portfolio through Thermo Fisher's installed base.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Invivoscribe, Inc. competitors and assessment

Company assessment

Direct peers

  • NeoGenomics Laboratories: Specialized oncology reference lab offering hematologic malignancy testing, MRD assays, and CDx services in the US and internationally. Direct competitor to Invivoscribe's LabPMM clinical lab and CDx franchise with significant overlap in lymphoma/leukemia molecular diagnostics.
  • Adaptive Biotechnologies: ClonoSEQ MRD assay and immunoSEQ clonality platform overlap directly with Invivoscribe's LymphoTrack and LeukoStrat MRD products for blood cancer MRD monitoring. Both companies use NGS-based receptor gene sequencing for clonal tracking.
  • Personalis: Cancer genomics company offering tumor profiling and MRD solutions (NeXT Personal) for biopharma and clinical use; competes with Invivoscribe's NGS panel/CDx/molecular diagnostic offering in oncology biomarker work.
  • Asuragen (Bio-Techne): Molecular diagnostics business of Bio-Techne that develops quantitative PCR kits (e.g., BCR-ABL, JAK2) for blood cancer monitoring with pharma CDx experience; competes with Invivoscribe's PCR-based IdentiClone, LeukoStrat, and quantitative oncology kits.

Broad incumbents

  • Foundation Medicine (Roche): Broad oncology NGS profiling and CDx developer owned by Roche; competes with Invivoscribe for biopharma CDx partnerships and hematologic panel testing, especially with its heme panel and global pharma services reach.
  • QIAGEN: Major molecular diagnostics and sample technologies company with companion diagnostic, IVD assay, and bioinformatics offerings; broad incumbent competing with Invivoscribe's assay kits, CDx, and bioinformatics software businesses.
  • Labcorp / Invitae (Archer): Labcorp acquired sequencing-based diagnostics and CDx assets including ArcherDX for hematologic fusion/mutation detection and inherited cancer testing; competes broadly with Invivoscribe's oncology NGS and CDx services through its central lab network.
  • Sysmex Corporation: Global hematology diagnostics leader with cell analyzers, flow cytometry, and growing molecular hemato-oncology franchise; broad incumbent in hematologic malignancy diagnostics overlapping Invivoscribe's LabPMM flow and NGS services.

Emerging players

  • Guardant Health: Liquid biopsy oncology testing and CDx company; while initially focused on solid tumors, expansion into blood-based cancer monitoring overlaps with Invivoscribe's hematologic MRD ambitions and CDx/biopharma partnership model.
  • HTG Molecular Diagnostics (now part of standard bio-tools): Molecular profiling company developing tissue and blood-based oncology biomarker assays and CDx partnerships for hematologic and solid tumor indications; an emerging peer in biomarker-driven CDx development similar to Invivoscribe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Invivoscribe, Inc. social profiles

Digital presence

Invivoscribe, Inc. compliance and trust

Trust signal

Compliance7 records

Invivoscribe, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invivoscribe, Inc. leadership team

Management profile

Number of profiles

Profiles3 records

Invivoscribe, Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Invivoscribe, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invivoscribe, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invivoscribe, Inc.

What does Invivoscribe, Inc. do?

Invivoscribe develops, manufactures, and commercializes cGMP precision diagnostic assay kits, bioinformatics software, and clinical laboratory services for hematologic malignancies, with a focus on companion diagnostics (CDx), clonality testing, and minimal residual disease (MRD) monitoring. Its flagship LeukoStrat CDx FLT3 Mutation Assay was the world's first FDA-approved companion diagnostic for AML and is approved for multiple targeted therapies across the USA, EU, Japan, and the UK. The company also operates the LabPMM global clinical laboratory network providing internationally standardized biomarker testing for patient care and pharmaceutical clinical trials.

Is Invivoscribe, Inc. a public or private company?

Invivoscribe, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Invivoscribe, Inc. founded?

Invivoscribe, Inc. was founded in 1995. It employs 101 to 250 people.

Where is Invivoscribe, Inc. based?

Invivoscribe, Inc. is headquartered in San Diego, United States, in the North America region.

How does Invivoscribe, Inc. make money?

Four revenue lines are on record. Assay Kits and Reagents Sales are the primary driver. The others are clinical Laboratory Testing Services (LabPMM), companion Diagnostic Development Partnerships and bioinformatics Software Licensing.

Who are Invivoscribe, Inc.'s main competitors?

Direct peers on record are NeoGenomics Laboratories, Adaptive Biotechnologies, Personalis and Asuragen (Bio-Techne). Broad incumbents are Foundation Medicine (Roche), QIAGEN, Labcorp / Invitae (Archer) and Sysmex Corporation. Emerging players are Guardant Health and HTG Molecular Diagnostics (now part of standard bio-tools).

Does Invivoscribe, Inc. have an API?

No public API is recorded for Invivoscribe, Inc..

What industry is Invivoscribe, Inc. in?

Invivoscribe, Inc.'s product category is Molecular Diagnostics for Hematologic Malignancies. Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogInvivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex SuiteInvivoscribe launched the complete LymphoTrack Flex suite, an NGS solution for clonality and MRD testing across lymphoid malignancies. The suite includes seven molecular targets and an automation-ready workflow with software for local or enterprise analysis.FinancialContent Business PageInvivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex SuiteInvivoscribe launched the LymphoTrack Flex suite, an NGS solution for tracking immunoglobulin and T-cell receptor gene rearrangements. The suite includes seven molecular targets and an automation-ready workflow for clonality and MRD testing. It supports both local and enterprise software for scalable laboratory use.AETOSWireEU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEAInvivoscribe's LeukoStrat CDx FLT3 Mutation Assay received EMA and BSI approval as a CE-marked IVD to aid selection of FLT3-ITD+ AML patients for VANFLYTA therapy. The PCR-based test detects FLT3 ITD and TKD mutations and is intended for use with XOSPATA or VANFLYTA in EU/EEA.AETOSWireInvivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and SwitzerlandInvivoscribe registered its LeukoStrat CDx FLT3 Mutation Assay in the UK and Switzerland, achieving MHRA and Swissmedic approval. The PCR-based test detects FLT3 ITD and TKD mutations in AML patients, enabling same-day results to guide targeted therapy decisions.AETOSWireInvivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD AssayInvivoscribe's LabPMM received New York State Department of Health approval to offer its FLT3 ITD MRD assay for detecting measurable residual disease in FLT3 ITD-mutated AML. The assay has an allele sensitivity of 5 x 10^-5 and aims to improve patient outcomes by guiding treatment decisions.AETOSWireInvivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay CertificationInvivoscribe's IdentiClone Dx IGH assay received IVDR Class C certification in the EU, making it the first IVDR-certified assay for detecting clonal immunoglobulin gene rearrangements in suspected B-cell lymphoproliferative disease. Commercial availability is anticipated by early April 2026.AETOSWireInvivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical WorkflowsInvivoscribe announced the PrepQuant System, an automated sample preparation platform integrating nucleic acid extraction, concentration, and quantification. Developed with Hitachi High-Tech, it is assay-agnostic and reduces lab costs and variability. First commercial shipments are planned for North America in August 2026, with European availability in January 2027.AETOSWireInvivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management WorldwideInvivoscribe launched the LeukoStrat KMT2A + MRD Assay, a digital PCR test for detecting KMT2A rearrangements in AML, with sensitivity down to 0.005%. The assay is available for research use and will soon be offered as a service in its LabPMM laboratories. Later this year, it will be enhanced with four additional rearrangements for ALL.AETOSWireInvivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex SuiteInvivoscribe launched the LymphoTrack Flex suite, an NGS solution for tracking immunoglobulin and T-cell receptor gene rearrangements. The suite includes seven molecular targets and an automation-ready workflow for clonality and MRD testing. It offers flexible software for local or centralized analysis.AETOSWireInvivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Tes...Invivoscribe began commercial shipments of PrepQuant systems in North America, an automated platform for DNA extraction and concentration from blood and plasma. The assay-agnostic system supports MRD assays and is designed for larger sample inputs. European availability is scheduled for early 2027.